Paper40429403
Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study.
Butuca A and 10 others. J Clin Med, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study. Papers, record 40429403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40429403
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| LBUS-IRG-2023 No. 3536/24.07.2023 | Lucian Blaga University of Sibiu | PubMed |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35497810 | Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death. | Kidney Int Rep | 2022 | https://conductscience.org/library/papers/35497810 | PubMed |
| 2 | 38020744 | A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. | Transpl Int | 2023 | https://conductscience.org/library/papers/38020744 | PubMed |
| 3 | 36819125 | Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. | Transpl Int | 2023 | https://conductscience.org/library/papers/36819125 | PubMed |
| 4 | 32404066 | Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients. | BMC Nephrol | 2020 | https://conductscience.org/library/papers/32404066 | PubMed |
| 5 | 34620231 | Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. | BMC Pharmacol Toxicol | 2021 | https://conductscience.org/library/papers/34620231 | PubMed |
| 6 | 37793748 | Outcomes of Heart Transplant Donation After Circulatory Death. | J Am Coll Cardiol | 2023 | https://conductscience.org/library/papers/37793748 | PubMed |
| 7 | 35720296 | Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience. | Front Immunol | 2022 | https://conductscience.org/library/papers/35720296 | PubMed |
| 8 | 17093248 | Rabbit antithymocyte globulin versus basiliximab in renal transplantation. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17093248 | PubMed |
| 9 | 34697664 | Immunosuppression and Kidney Transplantation. | Handb Exp Pharmacol | 2022 | https://conductscience.org/library/papers/34697664 | PubMed |
| 10 | 38665475 | European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study. | Transpl Int | 2024 | https://conductscience.org/library/papers/38665475 | PubMed |
| 11 | 25563998 | Pancreas transplant alone. | Curr Opin Organ Transplant | 2015 | https://conductscience.org/library/papers/25563998 | PubMed |
| 12 | 36986554 | A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/36986554 | PubMed |
| 13 | 33428661 | Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models. | PLoS One | 2021 | https://conductscience.org/library/papers/33428661 | PubMed |
| 14 | 32719676 | Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection. | Front Immunol | 2020 | https://conductscience.org/library/papers/32719676 | PubMed |
| 15 | 31405369 | Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. | BMC Res Notes | 2019 | https://conductscience.org/library/papers/31405369 | PubMed |
| 16 | 28434523 | Belatacept: Where the BENEFITS Outweigh the Risk. | Am J Kidney Dis | 2017 | https://conductscience.org/library/papers/28434523 | PubMed |
| 17 | 31649071 | Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. | Clin J Am Soc Nephrol | 2019 | https://conductscience.org/library/papers/31649071 | PubMed |
| 18 | 38790915 | Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance. | Biomedicines | 2024 | https://conductscience.org/library/papers/38790915 | PubMed |
| 19 | 32436821 | Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols. | Curr Pharm Des | 2020 | https://conductscience.org/library/papers/32436821 | PubMed |
| 20 | 19424038 | Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. | Transplantation | 2009 | https://conductscience.org/library/papers/19424038 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40429403
GET https://conductscience.org/api/papers/v1/40429403/references?page=2